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Background
Etanercept has been the only TNF antagonist licensed for
treatment of resistant polyarticular juvenile idiopathic
arthritis (JIA) and Adalimumab recently became the sec-
ond one. Our objective was to evaluate efficacy and safety
after switching from Etanercept to Adalimumab in JIA
patients.
Methods
Prospective data were obtained using the database of the
German Etanercept Registry. Reasons for switching to
Adalimumab were recorded. Efficacy was assessed using
the PedACR30/50/70 criteria. Safety assessments were
based on the reporting of adverse events (AE).
Results
A total of 33 patients initially treated with Etanercept were
switched to Adalimumab after a mean of 25.9 months
(range 3–87 months). Reasons for discontinuation of
Etanercept were inefficacy (n = 23, 65.8%), uveitis (n = 6,
17.1%), intolerance (n = 3, 8.6%) and patients' request (n
= 6, 17.1%). Follow up data on Adalimumab were
obtained from 12 patients for a range of 2 to 26 months
(mean 10.9 months). The maximum response rate of the
PedACR30/50/70 on Etanercept was 82.4%/73.5%/
67.6%. The last documented response rate on Etanercept
showed a decrease to 47.1%/35.3%/29.4% (PedACR30/
50/70). After switching to Adalimumab a maximum
PedACR30/50/70 of 75%/66.7%/50% compared to start
of Etanercept and 33.3/33.3/25 compared to start of Adal-
imumab was reached. Treatment on both drugs was safe
with no report of serious AE.
Conclusion
Although a number of patients have reached a good
PedACR response rate on Etanercept, treatment was unsat-
isfied and therefore it was switched to Adalimumab.
According to the PedACR only minor improvement was
observed after switching to Adalimumab.
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